The adjuvant use of trastuzumab, a monoclonal antibody that targets the HER2 receptor, combined with chemotherapy, has significantly improved patient outcomes in HER2+ breast cancer with 46–56% reduction in recurrence rates and a 37% improvement in overall survival [2,3,4]. This evidence concerns the gene ERBB2 and breast cancer.